News

All News

Press Releases

Media

All Videos

Digital Detail

Independent Corner

Insights

Interviews

Medical World News

Microsites

Peer Exchange

Perfect Consult

Podcasts

Practice Pearls

Student Voices

Webinars/Webcasts

Conferences

Conference Coverage

Conference Listing

Publications

All Publications

Author Submission

Clinical

503B Compounding Pharmacy

ADHD

Allergy

Alzheimer Disease

Anxiety

Asthma

Atopic Dermatitis

Biosimilars

Bipolar Disorder

Brain Health

Breast Cancer

C. Difficile

COPD

COVID Treatment

Cardiovascular Health

Cervical Cancer

Cholangiocarcinoma

Chronic Kidney Disease

Chronic Lymphocytic Leukemia

Colorectal Cancer

Coronavirus

Cough and Cold

Depression

Dermatology

Diabetes

Digestive Health

Dry Eye Disease

Epilepsy

Eye Care

Future of Pharmacy

Gastrointestinal Cancer

Gastrointestinal Health

Gout

Heart Failure

Hematology

Hepatitis

IVIG

Immunization

Immuno-oncology

Infectious Disease

Lung Cancer

Lymphoma

Macular Degeneration

Mental Health

Migraine

Multiple Myeloma

Multiple Sclerosis

Neurology

Neutropenia

Osteoporosis

Ovarian Cancer

Pain Management

Parkinson Disease

Pediatrics

Pharmacy Heroes

Pharmacy Management

Pneumococcal

PrEP

Prostate Cancer

Psoriasis

Psoriatic Arthritis

Reimbursement

Respiratory Syncytial Virus

Rheumatoid Arthritis

Schizophrenia

Skin Cancer

Sleep

Veterinary Pharmacy

Vitamins and Supplements

Weight Management

Women's Health

Zoster

Events

Upcoming Events

Upcoming Webinars

CME/CE

Resources

Cou-Co

Educated Patient

Information for the Pharmacist

Interactive Tools

Partners

Whiteboards

Subscribe

Print Subscription

eNewsletter

Ashley Gallagher is an assistant editor at 

®. She graduated from St. Bonaventure University in 2020 in journalism and mass communications. Previously, she worked as a pharmacy technician for a retail chain.

Articles

The MARIPOSA study evaluated amivantamab-vmjw (Rybrevant; Janssen Pharmaceutical) in combination with lazertinib compared to osimertinib and compared to lazertinib monotherapy in the first-line treatment of EGFR-mutated non–small cell lung cancer.

Topline Data Demonstrate Survival Improvement With Amivantamab-vmjw for NSCLC

The most persuasive reason for industry-academia collaboration is the many opportunities it opens for pharmacy students who may not have considered all the ways they can use their PharmD to serve the cause of humankind.

Bridging the Gap: Industry-Academia Collaboration in Pharmacy

The study authors suggest that after initiating alpelisib, patients should be proactive by improving glycemic status to reduce the risk of developing hyperglycemia.

Study Shows Association Between Alpelisib Treatment, Hyperglycemia in Patients with Metastatic Breast Cancer

Videos

Ruben A. Mesa, MD, FACP, discusses the results of the SIMPLIFY-1 and MOMENTUM trials and how the data led to the approval of momelotinib to treat intermediate or high-risk myelofibrosis in adult patients with anemia.

Lead Investigator Provides Insight Into FDA Approval of Momelotinib for Myelofibrosis

Pharmacy Times offers the latest news and insights for the pharmacy professional and solutions that impact the everyday practice of pharmacy.

About Us

Advertise

Contact Us

Editorial Staff

Privacy Policy

Terms & Conditions

Do Not Sell My Information

Pharmacy Times – Pharmacy Practice News and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Spotlight

Hospital

Oncology

Pharmacy Technician

Retail

Student

Clinical Role

Specialty Pharmacy

1rem

Authors

Although the prevalence of health system-based specialty pharmacies has grown steadily over the past decade, 2020 will mark a critical year.

Growth of Health System-Based Specialty Pharmacy to Continue in 2020, Reducing Cost of Care

Don Amorosi, Chief Operating Officer

Articles